论文部分内容阅读
目的:探讨在新辅助化疗后乳腺癌中Her-2和survivin的表达及意义。方法:用免疫组化的方法测定12例未化疗及73例新辅助化疗乳癌患者术后标本Her-2和survivin的表达状况。结果:新辅助化疗组的Her-2的阳性率较未化疗组低,survivin的表达较未化疗组低。新辅助化疗后Her-2与survivin明显相关。结论:Her-2、survivin及两者之间的关联可能作为乳腺癌新辅助化疗的一个作用靶点。
Objective: To investigate the expression and significance of Her-2 and survivin in breast cancer after neoadjuvant chemotherapy. Methods: Immunohistochemistry was used to detect the expression of Her-2 and survivin in 12 cases of non-chemotherapy and 73 cases of neoadjuvant chemotherapy breast cancer. Results: The positive rate of Her-2 in neoadjuvant chemotherapy group was lower than that in non-chemotherapy group, and the expression of survivin was lower than that in non-chemotherapy group. Her-2 was significantly associated with survivin after neoadjuvant chemotherapy. Conclusion: The relationship between Her-2, survivin and their relationship may serve as a target of neoadjuvant chemotherapy for breast cancer.